Your session is about to expire
← Back to Search
Electronic Clinical Decision Support Tool for Atrial Fibrillation (AF SWCRT-CDS Trial)
N/A
Waitlist Available
Led By Bory Kea, MD, MCR
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must be over 18 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, up to 4 years
Awards & highlights
AF SWCRT-CDS Trial Summary
This trial will test whether a clinical decision support tool can help doctors prescribe blood-thinners to AF patients who are at risk for stroke, and explore why doctors might not be prescribing them otherwise.
Who is the study for?
This trial is for adults over 18 with new-onset atrial fibrillation diagnosed in the emergency department, who haven't been prescribed oral anticoagulants recently. It's not for those with severe liver or kidney disease, recent major surgery, certain bleeding conditions, or if they're pregnant.Check my eligibility
What is being tested?
The study tests a Clinical Decision Support tool designed to help doctors decide when to prescribe blood thinners to prevent strokes in patients with atrial fibrillation. The trial randomly assigns periods of time when different EDs will start using the tool.See study design
What are the potential side effects?
Since this trial involves an electronic decision-making tool rather than medication, there are no direct side effects like you'd expect from drugs. However, indirect effects may include changes in how often blood thinners are prescribed.
AF SWCRT-CDS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 18 years old.
AF SWCRT-CDS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, up to 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, up to 4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients appropriately prescribed OACs after CDS tool implementation.
Secondary outcome measures
Clinician and patient feedback on acceptability and identification of barriers and facilitators to use of the tool.
AF SWCRT-CDS Trial Design
3Treatment groups
Experimental Treatment
Group I: Link-OutExperimental Treatment1 Intervention
Clinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.
Group II: BPA + Link-outExperimental Treatment1 Intervention
Clinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.
Group III: BPA + FHIRExperimental Treatment1 Intervention
Instead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.
Find a Location
Who is running the clinical trial?
Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
6,845,948 Total Patients Enrolled
3 Trials studying Atrial Fibrillation
2,586 Patients Enrolled for Atrial Fibrillation
Bory Kea, MD, MCRPrincipal InvestigatorOregon Health and Science University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a heart valve problem.I was hospitalized or had a stroke or death event at my first visit.I was diagnosed with atrial or paroxysmal fibrillation between 1/11/2022 and 12/31/2025.I have been prescribed blood thinners in the last 3 months or am managed by a blood thinner clinic.I have a low platelet count.I have not had recent surgery or injury to my brain, eye, or spinal cord.I am over 18 years old.I have large veins in my esophagus.I have not had major surgery in the last 72 hours.I left the hospital against medical advice.I do not have severe liver or kidney disease.I have severe or hard-to-control bleeding.
Research Study Groups:
This trial has the following groups:- Group 1: BPA + Link-out
- Group 2: BPA + FHIR
- Group 3: Link-Out
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this medical research still recruiting participants at the present time?
"Clinicaltrials.gov displays that this research has already finished its recruitment process, with the trial first posted on November 1st 2022 and last updated April 18th 2022. Despite this, there are still 477 other trials actively seeking participants currently."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger